Mark J. C. Nuijten
MEDTAP International
Amsterdam
Netherlands
Name/email consistency: high
- Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations. Nuijten, M.J. Pharmacoeconomics (2004)
- Pricing of pharmaceuticals. Assessing the pricing potential by a pricing matrix model. Nuijten, M.J., Kosa, J. Eur. J. Health. Econ (2004)
- Cost-effectiveness of enoxaparin as thromboprophylaxis in acutely ill medical patients in Spain. Nuijten, M.J., Villar, F.A., Kosa, J., Nadipelli, V., Rubio-Terrés, C., Suarez, C. Value. Health (2003)
- The incorporation of potential confounding variables in Markov models. Nuijten, M.J., Rutten, F. Pharmacoeconomics (2003)
- Modeling the cost-effectiveness and budgetary impact for subpopulations. Nuijten, M.J., Kosa, J., Engelfriet, P. Eur. J. Health. Econ (2003)
- Health care reform in six Central European countries. A focus on health economic requirements in the drug pricing and reimbursement processes. Nuijten, M.J., Szende, A., Kosa, J., Mogyorosy, Z., Kramberger, B., Nemecek, K., Tomek, D., Oreskovic, S., Laskowska, M. Eur. J. Health. Econ (2003)
- Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Nuijten, M.J., Hutton, J. Value. Health (2002)
- A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Nuijten, M.J., Engelfriet, P., Duijn, K., Bruijn, G., Wierz, D., Koopmanschap, M. Pharmacoeconomics (2001)
